<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432065</url>
  </required_header>
  <id_info>
    <org_study_id>2017-P-002731</org_study_id>
    <nct_id>NCT03432065</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders</brief_title>
  <official_title>A Pilot Study of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this exploratory 8-week pilot study is to evaluate the safety and&#xD;
      efficacy of buspirone for the treatment of anxiety in youth (ages 6-17 years) with autism&#xD;
      spectrum disorders. The study results will be used to generate hypotheses for a larger&#xD;
      randomized-controlled trial with explicit hypotheses and sufficient statistical power.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Child and Adolescent Symptom Inventory-5-Anxiety (CASI-Anx) Score</measure>
    <time_frame>Baseline to 8 Weeks</time_frame>
    <description>The primary outcome measure of efficacy will be assessed by the reduction in anxiety symptom severity as measured by a change from baseline on the Child and Adolescent Symptom Inventory-5-Anxiety (CASI-Anx) scores. Responders are defined as those who demonstrate a &gt;30% reduction on the CASI-Anx.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Buspirone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buspirone tablets will be administered twice daily, and will be titrated to a maximum daily dose of 60mg for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone</intervention_name>
    <description>Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.</description>
    <arm_group_label>Buspirone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants between 6 and 17 years of age&#xD;
&#xD;
          -  DSM-5 ASD diagnostic criteria as established by clinical diagnostic interview&#xD;
&#xD;
          -  Participants with a score of â‰¥60 or more on the Anxiety/Depression subscale of CBCL&#xD;
&#xD;
          -  Subjects can be taking psychotropic medications if they have been on the medication&#xD;
             for at least 4 weeks prior to initiating study treatment and if they are on a stable&#xD;
             dose, provided the medication is not listed in the Concomitant Medications section of&#xD;
             the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of active seizure disorder (EEG suggestive of seizure activity and/or history&#xD;
             of seizure in last 1 month)&#xD;
&#xD;
          -  Subjects with a medical condition or treatment that will either jeopardize subject&#xD;
             safety or affect the scientific merit of the study, including:&#xD;
&#xD;
          -  Pregnant or nursing females&#xD;
&#xD;
          -  Organic brain disorders&#xD;
&#xD;
          -  Uncorrected hypothyroidism or hyperthyroidism&#xD;
&#xD;
          -  Clinically significant abnormalities on ECG (e.g., QT prolongation, arrhythmia)&#xD;
&#xD;
          -  History of renal or hepatic impairment.&#xD;
&#xD;
          -  Clinically unstable psychiatric conditions or judged to be at serious suicidal risk&#xD;
&#xD;
          -  Current diagnosis of schizophrenia or bipolar disorder&#xD;
&#xD;
          -  History of substance use (except nicotine or caffeine) within past 3 months or urine&#xD;
             drug screen positive for substances of abuse&#xD;
&#xD;
          -  Current treatment with medication with primary central nervous system activity (as&#xD;
             specified in the Concomitant Medication section of the protocol)&#xD;
&#xD;
          -  A non-responder or history of intolerance to buspirone, after treatment at an adequate&#xD;
             dose and duration as determined by the clinician&#xD;
&#xD;
          -  Subjects currently taking monoamine oxidase inhibitors (MAOI) and/or CYP3A4 inducers&#xD;
             or inhibitors including nefazodone, diltiazem, verapamil, erythromaycin, itraconazole,&#xD;
             or rifampin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atilla Ceranoglu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chloe Hutt Vater, BA</last_name>
    <phone>617-724-7301</phone>
    <email>chuttvater@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Chloe Hutt Vater, BA</last_name>
      <phone>617-724-7301</phone>
      <email>chuttvater@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Tolga A Ceranoglu</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <keyword>Autism Spectrum Disorders</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Pervasive Developmental Disorders</keyword>
  <keyword>Buspar</keyword>
  <keyword>Buspirone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

